Use pattern and off-label use of atypical antipsychotics in bipolar disorder 1998-2002

American Health and Drug Benefits

Volumn 2, Issue 4, 2009, Pages 184-191

  Demland, Jeffrey A ^a   Jing, Yonghua ^b   Kelton, Christina M L ^c   Guo, Jeff J ^d   Li, Hong ^e   Wigle, Patricia R ^d  

^a Medpace ^*  (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^e BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHLORPROMAZINE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MIRTAZAPINE; NEFAZODONE; OLANZAPINE; OXCARBAZEPINE; PERPHENAZINE; TOPIRAMATE; TRAZODONE; VALPROATE SEMISODIUM; VENLAFAXINE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CEREBROVASCULAR DISEASE; COMORBIDITY; DATA BASE; DIABETES MELLITUS; FEMALE; HEALTH INSURANCE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OFF LABEL DRUG USE; PRESCRIPTION; REIMBURSEMENT; RISK BENEFIT ANALYSIS; SUBSTANCE ABUSE;

EID: 77953449409     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617-627.
2. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord. 1998;50:143-151.
3. Guo JJ, Keck PE Jr, Li H, et al. Treatment costs and health care utilization for patients with bipolar disorder in a large managed care population. Value Health. 2008;11:416-423.
4. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
5. Guo JJ, Keck PE, Li H, et al. Evolution of mood stabilizer utilization among patients with bipolar disorder in a managed care Medicaid program [abstract]. Pharmacotherapy. 2004;24:144.
6. US Food and Drug Administration. CDER new and generic drug approvals: 1998-2004. www.fda.gov/cder/approval. Accessed August 15, 2007.
7. Blumer JL. Off-label uses of drugs in children. Pediatrics. 1999;104: 598-609.
8. Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. BMJ. 2000; 320:79-82.
9. Nahata MC. Inadequate pharmacotherapeutic data for drugs used in children: what can be done? Paediatr Drugs. 1999;1:245-249.
10. O'Reilly J, Dalal A. Off-label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs. Ann Health Law. 2003;12:295-324.
11. Guglielmo WJ. Off-label marketing stirs a legal hornet's nest. Med Econ. 2006;83:47-49.
12. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166:1021-1026.
13. Chen H, Deshpande AD, Jiang R, et al. An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid population. Pharmacoepidemiol Drug Saf. 2005;14:629-638.
14. Chen H, Reeves JH, Fincham JE, et al. Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia Medicaid enrollees in 2001. J Clin Psychiatry. 2006;67:972-982.
15. Jing Y, Kelton CML, Guo JJ, et al. Price, utilization, and spending for antipsychotic medications in the Medicaid program. Drug Benefit Trends. 2007;19:27-41.
16. PHARMetrics Patient-CentricDatabase.Watertown,MA:April 25, 2007.
17. Guo JJ, Ludke RC, Heaton PC, et al. Characteristics and risk factor associated with high-costMedicaid recipients. Manag Care Interface. 2004; 17:20-27.
18. Hirschfeld RM, Calabrese JR, Weissman MM, et al. Screening for bipolar disorder in the community. J Clin Psychiatry. 2003;64:53-59.
19. Das AK, Olfson M, Gameroff MJ, et al. Screening for bipolar disorder in a primary care practice. JAMA. 2005;293:956-963.
20. Goodwin RD, Hoven CW. Bipolar-panic comorbidity in the general population: prevalence and associated morbidity. J Affect Disord. 2002; 70:27-33.
21. George EL, Miklowitz DJ, Richards JA, et al. The comorbidity of bipolar disorder and axis II personality disorders: prevalence and clinical correlates. Bipolar Disord. 2003;5:115-122.
22. Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy associated weight gain. J Clin Psychiatry. 2003;64:1426-1435.
23. Guo JJ, Keck PE Jr, Corey-Lisle PK, et al. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder. J Clin Psychiatry. 2006;67:1055-1061.
24. Krishnan KR. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med. 2005;67:1-8.
25. Culver JL, Arnow BA, Ketter TA. Bipolar disorder: improving diagnosis and optimizing integrated care. J Clin Psychol. 2007;63:73-92.
26. Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003;160:1651-1658.
27. Hirschfeld RM, Keck PE Jr, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry. 2004;161:1057-1065.
28. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ. 2002;167:1269-1270.
29. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(4 suppl):1-50.
30. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ. 2004;170:1395.
31. Kortepeter C, Chen M, Knudsen JF, et al. Clozapine and venous thromboembolism. Am J Psychiatry. 2002;159:876-877.
32. Smith DA, Beier MT. Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypotheses for an underlying mechanism. J Am Med Dir Assoc. 2004;5:129-132.
33. Lund BC, Perry PJ, Brooks JM, et al. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry. 2001;58:1172-1176.
34. Sumiyoshi T, Roy A, Jayathilake K, et al. The effect of hypertension and obesity on the development of diabetes mellitus in patients treated with atypical antipsychotic drugs. J Clin Psychopharmacol. 2004;24:452-454.